Dr. George Laliotis
Physician-scientist at Natera. Circulating tumour DNA, minimal residual disease and precision oncology.
A reading
of the life.
George is a physician-scientist working at the front edge of liquid biopsy — the practice of reading fragments of tumour DNA circulating in ordinary blood. At Natera he works on the oncology programmes built around minimal residual disease: finding the smallest possible signal that cancer is present, or that it has returned.
He advises NordicScan on how molecular signals sit alongside imaging. An MRI shows structure; blood shows biology. His interest is in what happens when a practice reads both, on the same person, year after year.
“Data is not an answer. The work is turning a signal into a decision a patient can actually act on.”
Where attention
is paid.
- 01Circulating tumour DNA (ctDNA)
- 02Minimal residual disease detection
- 03Precision oncology strategy
- 04Translational research & medical affairs
- MD
Medical degree, followed by residency training in Internal Medicine
- MPH · MHA
Graduate training in public health and health administration
- Research
Cancer biology and translational oncology research, Johns Hopkins Medicine
- Johns Hopkins
Research scientist, cancer biology and translational oncology
- Natera
Associate Director, Oncology Lifecycle Management — liquid biopsy and MRD programmes
- NordicScan
Advisor, molecular diagnostics and early detection
A modern
record.
- 01
Translational oncology and ctDNA research, Johns Hopkins Medicine
- 02
Oncology lifecycle and MRD programmes, Natera
- 03
Published work and commentary on precision diagnostics and AI in medicine
How to be
seen.
Advisory. Quarterly review of the biomarker programme.